Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →P2X7 receptors mediate ATP-induced inflammasome activation and IL-1β release from microglia and macrophages, contributing to neuroinflammation and chronic…
Eli Lilly has signed a global licensing deal worth up to $230 million for Asahi Kasei Pharma's experimental chronic pain drug AK1780, a P2X7 receptor…
In 2021, an estimated 51.6 million U.S. adults (20.9%) experienced chronic pain and 17.1 million (6.9%) experienced high-impact chronic pain. Prevalence was…
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
Eli Lilly licensed exclusive rights for AK1780 from Asahi Kasei Pharma, an orally bioavailable P2X7 receptor antagonist that completed Phase 1 dose and clinical pharmacology studies. Lilly paid $20M upfront with up to $210M in potential development and regulatory milestones.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / Asahi Kasei Pharma (this deal) | 2021 | $230M | — |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
← Browse all deals · How we score deals
More: 2021 deals · Eli Lilly and Company deals · Other deals